Citation Tools

Download PDFPDF
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

Download to a citation manager

Cite this article as:
EHLEN TG, HOSKINS PJ, MILLER D, et al
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer